Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for ...

The study’s small size limits interpretation, but it remains the largest real-world data available, experts said.

Substantial savings opportunities exist by using lower-cost biologics for patients with plaque psoriasis, according to one ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

In the Phase III SELECT-GCA trial, Rinvoq (upadacitinib) 15 mg with a 26-week glucocorticoid taper significantly improved ...

Japanese drug firm Chugai Pharmaceutical has established competitive advantages due to its alliance with majority shareholder Roche as well as its internal research and development engine. While ...

A new study published in the Journal of European Academy of Dermatology and Venerology showed that compared to patients on ...

IL-5 inhibitors lead to dramatic reductions in eosinophil levels within 3 days in five patients with drug reaction with ...

These new agents include the following: Dupixent is a first-in-class interleukin (IL)-4/IL-13 dual inhibitor that was ...

– Coherus to focus exclusively on its innovative novel oncology programs including: – LOQTORZI®, a revenue-generating and differentiated PD-1 inhibitor; – Casdozokitug, a first-in-class interleukin-27 ...

With a promising IL-36 inhibitor for atopic dermatitis (AD, or eczema) at the phase II stage, Turn Therapeutics Inc. has gained $75 million in post-public commitments and meanwhile is pursuing a ...

Department of Intensive Care Unit, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, Guangdong, 510095, China Department of Radiation Oncology, Affiliated Cancer ...